Something unusual is happening in UK gyms. The same drug that helped millions of people lose weight — semaglutide, sold as Ozempic and Wegovy — is now appearing alongside anabolic steroids in the stacks of serious bodybuilders and physique competitors. It is one of the most significant shifts in performance drug culture in years, and it comes with both genuine utility and real risks that most people are not talking about.
Why Bodybuilders Are Interested in GLP-1 Drugs
GLP-1 receptor agonists like semaglutide work by suppressing appetite, slowing gastric emptying, and improving insulin sensitivity. For a bodybuilder deep in a cutting phase — trying to get from 15% body fat down to stage-ready single digits — the appetite suppression alone is transformative. Hunger is the biggest obstacle in any serious cut, and semaglutide essentially removes it.
A 2025 study published in Drug and Alcohol Dependence documented the growing practice of off-label GLP-1 use among online bodybuilding communities, finding that users were primarily motivated by accelerated fat loss during cutting phases and were well aware they were operating outside approved medical use. The study noted that harm reduction information was being shared communally — users advising each other on dosing, timing, and how to stack GLP-1 drugs with existing compounds to offset the risks.
The Muscle Loss Problem — And How Bodybuilders Are Solving It
Here is the central problem: GLP-1 drugs cause weight loss, but not exclusively from fat. Clinical trial data on semaglutide shows that roughly 33–40% of total weight lost comes from lean mass rather than adipose tissue. For someone losing 15kg, that could mean 5–6kg of muscle gone alongside the fat — an unacceptable trade-off for anyone who has spent years building their physique.
The bodybuilding community’s solution is straightforward: stack the GLP-1 drug with anabolic compounds specifically chosen to protect and preserve lean mass during the caloric deficit. The compounds most commonly used for this purpose include:
- Anavar (Oxandrolone) — The first choice for most users. Anavar at 50mg/day is strongly anti-catabolic, preserving muscle tissue during aggressive cuts without significant water retention or harsh side effects. Its mild androgenic profile makes it particularly well-suited to the lean, dry look most GLP-1 users are pursuing. Crucially, Anavar does not significantly suppress appetite further — a concern when appetite is already suppressed by semaglutide.
- HGH (Human Growth Hormone) — HGH at 2–3IU/day is arguably the ideal GLP-1 companion. Growth hormone directly stimulates lipolysis (fat breakdown) while simultaneously being strongly muscle-sparing — it preserves lean mass even in severe caloric deficits. The combination of semaglutide’s appetite suppression and HGH’s direct fat mobilisation creates a powerful synergy for body recomposition.
- Winstrol (Stanozolol) — For users in the final 6–8 weeks before a competition or photoshoot, Winstrol’s hardening effect complements the drying effect of aggressive GLP-1-assisted cutting. It adds no water and actively improves the visual separation between muscle groups as body fat drops.
- Testosterone Cypionate — A low TRT-dose testosterone base (150–200mg/week) is recommended by most experienced users during any GLP-1 cycle. Semaglutide’s appetite suppression can compound with the testosterone suppression of any other steroid in the stack, and maintaining baseline testosterone prevents the low-energy, low-libido crash that derails many users.
The Real Risks — What UK Users Need to Know
The combination carries risks that deserve honest discussion rather than dismissal.
Protein intake becomes critical. Semaglutide suppresses appetite so effectively that many users struggle to hit adequate protein targets. On a standard cutting diet without GLP-1, most bodybuilders eat 2.2–2.8g of protein per kg of bodyweight. On semaglutide, consuming that volume of food becomes genuinely difficult. Protein shakes and structured meal timing become non-negotiable, not optional.
Hypoglycaemia risk is real. When semaglutide’s blood sugar-lowering effect is combined with the glucose-uptake effects of anabolic steroids — particularly compounds like Anadrol which affect insulin sensitivity — blood sugar can drop unpredictably. Users who also include T3 (Liothyronine) in their stack for additional fat loss are adding another variable to an already complex hormonal picture.
Muscle cramps and electrolyte depletion. Semaglutide reduces total food intake significantly, which often means reduced sodium, potassium, and magnesium intake. Combined with the increased perspiration typical of steroid use, electrolyte imbalances and severe muscle cramps are commonly reported.
Gastric side effects stack. Both semaglutide and oral steroids like Anavar can cause gastrointestinal distress. Running both simultaneously increases the likelihood of nausea, reduced appetite compliance, and in some cases the practical inability to eat enough — which counterproductively worsens muscle loss.
The Harm Reduction Approach Most UK Users Are Taking
Based on what circulates in UK bodybuilding communities, the most common harm reduction protocol for GLP-1 + AAS stacking looks like this:
- Start semaglutide at a low dose (0.25–0.5mg/week) and titrate slowly over 6–8 weeks before adding any anabolic compounds
- Use injectable Anavar or oral Anavar at no more than 50mg/day as the primary muscle-preserving agent — avoid harsher orals like Anadrol or Dianabol which worsen GI side effects
- Maintain a testosterone base of 150–200mg/week throughout
- Run HGH at 2IU/day if budget allows — this appears to significantly improve the muscle retention outcome
- Prioritise liquid protein (shakes, Greek yoghurt, eggs) over solid meals when appetite suppression makes eating difficult
- Supplement with electrolytes daily and monitor for dizziness or cramping
- Run standard Clomid PCT after the cycle as suppression still occurs regardless of the GLP-1 component
The Bigger Picture: What This Tells Us About Where Performance Drug Culture Is Going
The GLP-1 trend is a symptom of something broader. The line between medical pharmaceuticals and performance enhancement continues to blur. Drugs developed for type 2 diabetes are being repurposed for elite fat loss. Peptides developed in research labs are being self-administered by recreational athletes. TRT prescriptions in the UK have increased 52% since 2020 as men increasingly pursue hormonal optimisation rather than waiting for the NHS to acknowledge their symptoms.
For bodybuilders and physique athletes, this means the toolkit available — and the complexity of managing it safely — has expanded significantly. GLP-1 drugs are not going away. Understanding how they interact with traditional anabolic compounds is not optional for anyone serious about optimising their results.
The compounds most relevant to a GLP-1 cutting stack — Anavar, HGH, Winstrol, low-dose Testosterone Cypionate, and Anastrozole for estrogen management — are available in our catalogue. Browse the full Cutting range or view our pre-built Cycle packages.
